4//SEC Filing
Evans John M. 4
Accession 0001193125-25-230084
CIK 0001745999other
Filed
Oct 2, 8:00 PM ET
Accepted
Oct 3, 4:05 PM ET
Size
15.3 KB
Accession
0001193125-25-230084
Insider Transaction Report
Form 4
Evans John M.
DirectorCEO
Transactions
- Exercise/Conversion
Common Stock
2025-10-02$0.67/sh+25,000$16,750→ 1,011,667 total - Sale
Common Stock
2025-10-02$24.63/sh−25,000$615,668→ 986,667 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-10-02−25,000→ 19,336 totalExercise: $0.67Exp: 2028-05-08→ Common Stock (25,000 underlying) - Exercise/Conversion
Common Stock
2025-10-01$0.67/sh+25,000$16,750→ 1,011,667 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-10-01−25,000→ 44,336 totalExercise: $0.67Exp: 2028-05-08→ Common Stock (25,000 underlying) - Sale
Common Stock
2025-10-01$24.51/sh−25,000$612,655→ 986,667 total
Holdings
- 103,000(indirect: By Trust)
Common Stock
Footnotes (5)
- [F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025.
- [F2]Includes 418 shares acquired by the Reporting Person under the Beam Therapeutics Inc. ("BEAM") Amended and Restated 2019 Employee Stock Purchase Plan on September 30, 2025.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $24.14 to $24.92, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $24.22 to $25.05, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F5]On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,396 shares upon the achievement of a closing hurdle following BEAM's initial public offering (which closing price hurdle was achieved) (the "Price Condition"). The portion of the award subject to the Price Condition vested in three equal installments on December 21, June 30, 2022, and December 31, 2022.
Documents
Issuer
Beam Therapeutics Inc.
CIK 0001745999
Entity typeother
Related Parties
1- filerCIK 0001786304
Filing Metadata
- Form type
- 4
- Filed
- Oct 2, 8:00 PM ET
- Accepted
- Oct 3, 4:05 PM ET
- Size
- 15.3 KB